- Home
- CXII vs STTK Comparison
CXII vs STTK Comparison
Compare CXII & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CXII | STTK |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 588.8M | 538.3M |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CXII | STTK |
|---|---|---|
| Price | $10.65 | $7.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 83.4K | ★ 1.2M |
| Earning Date | N/A | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.05 | $0.71 |
| 52 Week High | $10.90 | $8.33 |
Technical Indicators
Market Signals| Indicator | CXII | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 61.89 | N/A |
| Support Level | $10.59 | N/A |
| Resistance Level | $10.87 | N/A |
| Average True Range (ATR) | 0.12 | 0.00 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 66.67 | 0.00 |
Price Performance
Historical ComparisonAbout CXII Churchill Capital Corp XII Class A Ordinary Shares
Churchill Capital Corp XII is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.